{"schema_version":"secwatch.filing_event.v1","accession":"0001854270-23-000102","form_type":"8-K","ticker":"SNTI","cik":"0001854270","company_name":"Senti Biosciences, Inc.","filed_at":"2023-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.793744+00:00","generated_at":"2026-06-11T15:29:07.276107+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Senti Bio receives Nasdaq deficiency notice for bid price below $1.00 per share","bullets":["Received Nasdaq notice on Aug 7, 2023 for bid price below $1.00 for 30 consecutive days.","Has 180 days until Feb 5, 2024 to regain compliance with Minimum Bid Price Requirement.","To regain compliance, closing bid must be at least $1.00 for 10 consecutive trading days.","Company may consider reverse stock split subject to board and stockholder approval.","Failure to regain compliance could lead to delisting; may appeal or transfer to Nasdaq Capital Market."],"urls":{"canonical":"https://secwatch.observer/filing/0001854270-23-000102","json":"https://secwatch.observer/filing/0001854270-23-000102.json","markdown":"https://secwatch.observer/filing/0001854270-23-000102.md","text":"https://secwatch.observer/filing/0001854270-23-000102.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1854270/000185427023000102/0001854270-23-000102-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1854270/000185427023000102/snti-20230807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T15:29:07.276107+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b00204071e59a545fb7bfb5f5a4a1a67706295a4","claim":"Senti Biosciences, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).","evidence_excerpt":"August 7, 2023, Senti Biosciences, Inc. (the “ Company ” or “ Senti Bio ”) received written notice (the “ Notice ”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that, for the last 30 consecutive trading days, the closing bid price of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), had closed below the minimum bid price requirement of $1.00 per share for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “ Minimum Bid Price Requirement ”). The Notice has no","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1854270/000185427023000102/0001854270-23-000102-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"noncompliance notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5450(a)(1), 5810(c)(3)(A)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}